183 related articles for article (PubMed ID: 27856288)
1. A Multicenter Randomized Controlled Trial Evaluating a Cx43-Mimetic Peptide in Cutaneous Scarring.
Grek CL; Montgomery J; Sharma M; Ravi A; Rajkumar JS; Moyer KE; Gourdie RG; Ghatnekar GS
J Invest Dermatol; 2017 Mar; 137(3):620-630. PubMed ID: 27856288
[TBL] [Abstract][Full Text] [Related]
2. Connexin 43-Based Therapeutics for Dermal Wound Healing.
Montgomery J; Ghatnekar GS; Grek CL; Moyer KE; Gourdie RG
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914066
[TBL] [Abstract][Full Text] [Related]
3. Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding.
Ghatnekar GS; O'Quinn MP; Jourdan LJ; Gurjarpadhye AA; Draughn RL; Gourdie RG
Regen Med; 2009 Mar; 4(2):205-23. PubMed ID: 19317641
[TBL] [Abstract][Full Text] [Related]
4. The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.
Ghatnekar GS; Grek CL; Armstrong DG; Desai SC; Gourdie RG
J Invest Dermatol; 2015 Jan; 135(1):289-298. PubMed ID: 25072595
[TBL] [Abstract][Full Text] [Related]
5. Topical administration of a connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: A multicenter, randomized trial.
Grek CL; Prasad GM; Viswanathan V; Armstrong DG; Gourdie RG; Ghatnekar GS
Wound Repair Regen; 2015; 23(2):203-12. PubMed ID: 25703647
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 reduces scar formation in both animal and human cutaneous wounds: results of two preclinical and phase II randomized control studies.
Kieran I; Knock A; Bush J; So K; Metcalfe A; Hobson R; Mason T; O'Kane S; Ferguson M
Wound Repair Regen; 2013; 21(3):428-36. PubMed ID: 23627460
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of the embrace advanced scar therapy device to reduce incisional scar formation.
Longaker MT; Rohrich RJ; Greenberg L; Furnas H; Wald R; Bansal V; Seify H; Tran A; Weston J; Korman JM; Chan R; Kaufman D; Dev VR; Mele JA; Januszyk M; Cowley C; McLaughlin P; Beasley B; Gurtner GC
Plast Reconstr Surg; 2014 Sep; 134(3):536-546. PubMed ID: 24804638
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
Ferguson MW; Duncan J; Bond J; Bush J; Durani P; So K; Taylor L; Chantrey J; Mason T; James G; Laverty H; Occleston NL; Sattar A; Ludlow A; O'Kane S
Lancet; 2009 Apr; 373(9671):1264-74. PubMed ID: 19362676
[TBL] [Abstract][Full Text] [Related]
9. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.
Ferguson MW; O'Kane S
Philos Trans R Soc Lond B Biol Sci; 2004 May; 359(1445):839-50. PubMed ID: 15293811
[TBL] [Abstract][Full Text] [Related]
10. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial.
Bush J; Duncan JAL; Bond JS; Durani P; So K; Mason T; O'Kane S; Ferguson MWJ
Plast Reconstr Surg; 2010 Nov; 126(5):1604-1615. PubMed ID: 21042116
[TBL] [Abstract][Full Text] [Related]
11. The connexin 43 carboxyl terminal mimetic peptide αCT1 prompts differentiation of a collagen scar matrix in humans resembling unwounded skin.
Montgomery J; Richardson WJ; Marsh S; Rhett JM; Bustos F; Degen K; Ghatnekar GS; Grek CL; Jourdan LJ; Holmes JW; Gourdie RG
FASEB J; 2021 Aug; 35(8):e21762. PubMed ID: 34246197
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Burns Treated With Autologous Cultured Proliferating Epidermal Cells: A Prospective Randomized Multicenter Intrapatient Comparative Trial.
Gardien KL; Marck RE; Bloemen MC; Waaijman T; Gibbs S; Ulrich MM; Middelkoop E;
Cell Transplant; 2016; 25(3):437-48. PubMed ID: 26419871
[TBL] [Abstract][Full Text] [Related]
13. Skin closure methods after single port laparoscopic surgery: a randomized clinical trial.
Park SY; Kim KH; Yuk JS; Ji HY; Lee JH
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():8-12. PubMed ID: 25827078
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of connexin 43 in human gingival wound healing and fibroblasts.
Tarzemany R; Jiang G; Larjava H; Häkkinen L
PLoS One; 2015; 10(1):e0115524. PubMed ID: 25584940
[TBL] [Abstract][Full Text] [Related]
15. [Inhibiting scar formation in rat cutaneous wounds by blocking TGF-beta signaling].
Liu W; Chua CH; Wu XL; Wang DR; Yin DM; Cui L; Cao YL; Longaker MT
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):31-6. PubMed ID: 12757642
[TBL] [Abstract][Full Text] [Related]
16. Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat.
Rodgers KE; Ellefson DD; Espinoza T; Roda N; Maldonado S; Dizerega GS
Wound Repair Regen; 2005; 13(3):309-17. PubMed ID: 15953051
[TBL] [Abstract][Full Text] [Related]
17. Improved scar quality following primary and secondary healing of cutaneous wounds.
Atiyeh BS; Amm CA; El Musa KA
Aesthetic Plast Surg; 2003; 27(5):411-7. PubMed ID: 14648065
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the efficacy and tolerability of a unique topical scar product vs white petrolatum following shave biopsies.
Kircik LH
J Drugs Dermatol; 2013 Jan; 12(1):86-90. PubMed ID: 23377333
[TBL] [Abstract][Full Text] [Related]
19. The effects of brain natriuretic peptide on scar formation in incisional rat wounds.
Taira BR; Singer AJ; McClain SA; Zimmerman T
Acad Emerg Med; 2008 Oct; 15(10):945-8. PubMed ID: 18795903
[TBL] [Abstract][Full Text] [Related]
20. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7).
Rodgers KE; Espinoza T; Felix J; Roda N; Maldonado S; diZerega G
Plast Reconstr Surg; 2003 Mar; 111(3):1195-206. PubMed ID: 12621191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
